Endocrinology Medical News about lipid-lowering;coronary heart disease benefits;blood pressure

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Coronary heart disease benefits from blood pressure and lipid-lowering
International Journal of Cardiology, 06/15/09

Sever PS et al. – Coronary heart disease (CHD) benefits associated with blood pressure (BP) and lipid lowering were larger than predicted by previous observational and trial data. Compared with pre-trial treatment, treating an estimated 55 pts with the amlodipine-based regimen and atorvastatin would prevent 1 CHD event per year.

Methods

Report of analyses on combined benefits of atorvastatin and an amlodipine-based regimen for CHD events in hypertensive pts in Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Randomization of 19,342 hypertensive pts to either an amlodipine or atenolol-based regimen in ASCOT Blood Pressure-Lowering Arm (BPLA)
Further randomization 10,305 subjects with total cholesterol ≤6.5 mmol/L to atorvastatin 10 mg or placebo in Lipid-Lowering Arm (LLA)
Estimates of CHD risk at baseline based on Framingham algorithm compared with observed and predicted event rates throughout ASCOT-LLA

Results

Estimated baseline Framingham risk of CHD events: 22.8 / 1000 pt yrs
After 3.3 yrs, when LLA stopped, actual CHD event rate was 4.8 / 1000 pt years -- 79% reduction in pts assigned amlodipine-based treatment and atorvastatin

<< Previous
The relationship between depression and diabetes mellitus:...

Next >>
Treatment Modalities for Graves' Ophthalmopathy - Systematic...